cached image

Douglas R. Galasko, MD

Affiliations: 
Neuroscience University of California, San Diego, La Jolla, CA 
Area:
Dementia
Website:
http://neurograd.ucsd.edu/faculty/detail.php?id=30
Google:
"Douglas Galasko"
Bio:

http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=73

http://ucsd.photobooks.com/directory/profile.asp?setsize=10000&dbase=main&pict_id=0001460

Mean distance: 19.84 (cluster 32)
 
Cross-listing: Alzheimer's Tree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Tsiknia AA, Sundermann EE, Reas ET, et al. (2022) Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity. Alzheimer's Research & Therapy. 14: 160
Caldwell AB, Anantharaman BG, Ramachandran S, et al. (2022) Transcriptomic profiling of sporadic Alzheimer's disease patients. Molecular Brain. 15: 83
Salmon DP, Smirnov DS, Coughlin DG, et al. (2022) Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease. Neurology
Gollan TH, Stasenko A, Li C, et al. (2022) Autocorrection if→of function words in reading aloud: A novel marker of Alzheimer's risk. Neuropsychology
Tian C, Stewart T, Hong Z, et al. (2022) Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Tsiknia AA, Edland SD, Sundermann EE, et al. (2022) Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. Molecular Psychiatry
Mozersky J, Roberts SJ, Rumbaugh M, et al. (2022) Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants. Journal of Alzheimer's Disease : Jad
Bernier RA, Banks SJ, Panizzon MS, et al. (2022) The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum. Alzheimer's & Dementia (Amsterdam, Netherlands). 14: e12284
Smirnov D, Galasko D. (2022) Dynamics of neuroinflammation in Alzheimer's disease. The Lancet. Neurology. 21: 297-298
Smirnov DS, Ashton NJ, Blennow K, et al. (2022) Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica
See more...